This study is now under peer review during March 26 to 28, 2018; the reports can be found here (NTP TR 595; rats) and here (NTP TR 596; mice). It has been able to submit comments and our views can be found here.
Our overall evaluation of levels of evidence of carcinogenic activity are:
Glioma: Clear evidence
Meningioma: Equivocal evidence
Vestibular schwannoma (acoustic neuroma): Clear evidence
Pituitary tumor (adenoma): Equivocal evidence
Thyroid cancer: Some evidence
Malignant lymphoma: Equivocal evidence
Skin (cutaneous tissue): Equivocal evidence
Multi-site carcinogen: Some evidence
Based on the IARC preamble to the monographs, RF radiation should be classified as Group 1: The agent is carcinogenic to humans.
’This category is used when there is sufficient evidence of carcinogenicity in humans. Exceptionally, an agent may be placed in this category when evidence of carcinogenicity in humans is less than sufficient but there is sufficient evidence of carcinogenicity in experimental animals and strong evidence in exposed humans that the agent acts through a relevant mechanism of carcinogenicity.’ (http://monographs.iarc.fr/ENG/Preamble/currentb6evalrationale0706.php)